METHOD FOR PREDICTING THE SURVIVAL PERIOD OF PATIENTS WITH THE CLINICAL COURSE OF HIV AND TUBERCULOSIS COINFECTION, ACCOMPANIED BY MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS Russian patent published in 2022 - IPC G01N33/50 A61B5/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to infectious diseases, phthisiology and therapy, and can be used to predict the survival period of patients with the clinical course of HIV and tuberculosis coinfection (HIV/TB), accompanied by multidrug-resistant Mycobacterium tuberculosis. The essence of the method: in patients with detected multidrug resistant Mycobacterium tuberculosis, venous blood samples are taken, the number of CD4 lymphocytes and the concentration of nonspecific total immunoglobulins IgE (IU/ml), IgM (mg/ml), IgA (mg/ml) and secretory IgA (mg/l) in blood plasma are determined, the survival coefficient (SC) is calculated equal to the ratio of the product of their concentrations to the number of CD4 lymphocytes in 1 ml of blood. With SC equal to or less than 350, the life expectancy of patients is predicted to be equal to or more than 600 days, and with SC more than 350, the life expectancy of patients is predicted to be less than 600 days from the date of blood sampling for the quantitative determination of immunoglobulins.

EFFECT: method makes it possible to predict the survival time of hospitalized patients with HIV/TB coinfection with MDR MBT receiving anti-tuberculosis and antiretroviral therapy has the highest possible sensitivity, high prognostic value, is easy to perform, safe for the patient, relatively inexpensive and can be included in the parameters of a laboratory study as a criterion for the predicted survival of patients.

1 cl, 1 dwg, 4 tbl, 3 ex